Brief: NS Pharma FDA Granted Rare Pediatric Disease Designation To NS-089/NCNP-02 For Duchenne Muscular Dystrophy Amenable To Exon 44 Skipping Therapy

Nippon Shinyaku

07/07/2023 13:10

July 7 (Reuters) - Nippon Shinyaku Co Ltd  4516.T :
    * FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION TO
NS-089/NCNP-02
FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    * NS PHARMA: FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION
TO
NS-089/NCNP-02 FOR DUCHENNE MUSCULAR DYSTROPHY AMENABLE TO EXON
44 SKIPPING THERAPY

Source text for Eikon:  ID:nPn16b1M8a 
Further company coverage:  4516.T 

 ((reuters.briefs@thomsonreuters.com;))